Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Marksans Pharma Ltd - 524404 - Board to consider FY21 results & Dividend on May 31, 2021

 Marksans Pharma Ltd has informed BSE that the Meeting of the Board of Directors of the Company will be held on May 31, 2021, to consider and approve the Annual Audited Financial Results of the Company (both Standalone and Consolidated) for the Financial Year ended March 31, 2021. The Board of Directors will also consider recommendation of dividend, if any, forthe Financial Year 2020-21.Further, as per the Insider Trading Code of the Company, the Trading Window for dealing in Company's shares has been closed for the Company's insiders from April 01, 2021 and will remain closed till Forty-Eight hours after the announcement of the Financial Results on May 31, 2021.
24-05-2021
Bigul

Marksans Pharma Ltd - 524404 - Board Meeting Intimation for Notice Of Board Meeting

 MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/05/2021 ,inter alia, to consider and approve the Annual Audited Financial Results of the Company (both Standalone and Consolidated) for the Financial Year ended 31st March, 2021. The Board of Directors will also consider recommendation of dividend, if any, for the Financial Year 2020-21.
24-05-2021
Bigul

MARKSANS PHARMA LTD. - 524404 - Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 We enclose herewith Certificate issued by S. S. Rauthan & Associates, Company Secretaries for the half year ended 31st March, 2021 as required under Regulation 40(9) & 40 (10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
21-04-2021
Bigul

MARKSANS PHARMA LTD. - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2021 received from Bigshare Services Private Limited, Registrar and Transfer Agent of the Company.
15-04-2021
Bigul

MARKSANS PHARMA LTD. - 524404 - Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

 Please find enclosed herewith Compliance Certificate pursuant to Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 31st March, 2021.
15-04-2021
Bigul

MARKSANS PHARMA LTD. - 524404 - Statement Of Investor Complaints For The Quarter Ended March 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Harshavardhan PanigrahiDesignation :- Company Secretary and Compliance Officer
15-04-2021
Bigul

Marksans Pharma Ltd - 524404 - Shareholding for the Period Ended March 31, 2021

 Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here
14-04-2021
Bigul

MARKSANS PHARMA LTD. - 524404 - Declaration Regarding Non Applicability Of SEBI Circular Dated 26Th November, 2018

 We confirm that we are not a Large Corporate as per the applicability criteria given under the SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.
11-04-2021
Bigul

MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window

 In terms of the Company''s Code of Conduct to Regulate, Monitor and Report Trading by designated persons framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the trading window for dealing in the securities of Marksans Pharma Limited (the Company) for the insiders of the Company will remain closed from Thursday, 1st April, 2021 till 48 hours after the declaration of financial results for the quarter and financial year ended 31st March, 2021. The date of declaration of financial results will be intimated separately in due course of time. Designated Persons, Employees and other insiders of the Company and/or their immediate relatives shall not trade in the securities of the Company during the aforesaid period of closure of trading window.
31-03-2021
Bigul

Marksans Pharma Ltd - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby furnish the details of loss of share certificates and request for issue of duplicate share certificate reported by shareholders of the Company, received from our Registrar and Transfer Agent, Bigshare Services Private Limited on March 30, 2021.
31-03-2021
Next Page
Close

Let's Open Free Demat Account